title: Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study.
abstract: OBJECTIVE
  Infliximab is the first anti-TNFalpha accepted by the Food and Drug Administration for use in inflammatory bowel disease treatment. Few clinical, biological and genetic factors tend to predict response in Crohn's disease (CD) patient subcategories, none widely predicting response to infliximab.
  
  
  METHODS
  Twenty CD patients showing clinical response or non response to infliximab were used for serum proteomic profiling on Surface Enhanced Lazer Desorption Ionisation-Time of Flight-Mass Spectrometry (SELDI-TOF-MS), each before and after treatment. Univariate and multivariate data analysis were performed for prediction and characterization of response to infliximab.
  
  
  RESULTS
  We obtained a model of classification predicting response to treatment and selected relevant potential biomarkers, among which platelet aggregation factor 4 (PF4). We quantified PF4, sCD40L and IL-6 by ELISA for correlation studies.
  
  
  CONCLUSIONS
  This first proteomic pilot study on response to infliximab in CD suggests association between platelet metabolism and response to infliximab and requires validation studies on a larger cohort of patients.
authors.affiliation: Laboratory of Clinical Chemistry, GIGA Research, University of Liège, Belgium.
authors.forename: Marie-Alice
authors.initials: MA
authors.lastname: Meuwis
authors.forename: Marianne
authors.initials: M
authors.lastname: Fillet
authors.forename: Laurence
authors.initials: L
authors.lastname: Lutteri
authors.forename: Raphaël
authors.initials: R
authors.lastname: Marée
authors.forename: Pierre
authors.initials: P
authors.lastname: Geurts
authors.forename: Dominique
authors.initials: D
authors.lastname: de Seny
authors.forename: Michel
authors.initials: M
authors.lastname: Malaise
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Chapelle
authors.forename: Louis
authors.initials: L
authors.lastname: Wehenkel
authors.forename: Jacques
authors.initials: J
authors.lastname: Belaiche
authors.forename: Marie-Paule
authors.initials: MP
authors.lastname: Merville
authors.forename: Edouard
authors.initials: E
authors.lastname: Louis
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D023201:CD40 Ligand / Q000097:blood; D003424:Crohn Disease / Q000097:blood / Q000188:drug therapy*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D000069285:Infliximab; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010865:Pilot Projects; D010978:Platelet Factor 4 / Q000097:blood; D011379:Prognosis; D040901:Proteomics; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D015415:Biomarkers; D015850:Interleukin-6; D023201:CD40 Ligand; D010978:Platelet Factor 4; D000069285:Infliximab